Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis.

Sargsyan SA, Serkova NJ, Renner B, Hasebroock KM, Larsen B, Stoldt C, McFann K, Pickering MC, Thurman JM.

Kidney Int. 2012 Jan;81(2):152-9. doi: 10.1038/ki.2011.332. Epub 2011 Sep 28.

2.

Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice.

Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL, Holers VM, Thurman JM.

Radiology. 2010 May;255(2):517-26. doi: 10.1148/radiol.09091134. Epub 2010 Mar 23.

3.

Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.

Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS.

Kidney Int. 2004 Jan;65(1):129-38.

4.

Recipe for a new imaging biomarker: carefully combine target, reagent, and technology.

Kobayashi H, Choyke PL.

Kidney Int. 2012 Jan;81(2):129-31. doi: 10.1038/ki.2011.374.

5.

Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.

Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS.

J Immunol. 2001 May 15;166(10):6444-51.

6.

Complement receptor type 2–conjugated superparamagnetic iron oxide nanoparticles.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jul 23 [updated 2010 Dec 29].

7.

Expression of glomerular heparan sulphate domains in murine and human lupus nephritis.

Rops AL, van den Hoven MJ, Bakker MA, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, van der Vlag J, Berden JH.

Nephrol Dial Transplant. 2007 Jul;22(7):1891-902. Epub 2007 Jun 5. Erratum in: Nephrol Dial Transplant. 2007 Aug;22(8):2416.

8.

Complement factor H deficiency accelerates development of lupus nephritis.

Bao L, Haas M, Quigg RJ.

J Am Soc Nephrol. 2011 Feb;22(2):285-95. doi: 10.1681/ASN.2010060647. Epub 2010 Dec 9.

9.

Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.

Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS.

J Immunol. 2000 Jan 15;164(2):786-94.

10.

Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.

Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ.

J Immunol. 2002 Apr 1;168(7):3601-7.

11.

Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.

Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Gröne HJ, Schlöndorff D.

FASEB J. 2004 Mar;18(3):534-6. Epub 2004 Jan 20.

12.

Microarray analysis of glomerular gene expression in murine lupus nephritis.

Teramoto K, Negoro N, Kitamoto K, Iwai T, Iwao H, Okamura M, Miura K.

J Pharmacol Sci. 2008 Jan;106(1):56-67. Epub 2008 Jan 11.

13.

Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis.

Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, Oates JC.

PLoS One. 2013 May 31;8(5):e64650. doi: 10.1371/journal.pone.0064650. Print 2013.

14.
15.

Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.

Oates JC, Halushka PV, Hutchison FN, Ruiz P, Gilkeson GS.

Am J Med Sci. 2011 Feb;341(2):101-5. doi: 10.1097/MAJ.0b013e3181f56d2c.

16.

Augmentation of osteopontin expression in renal tubuli is independent of a histopathological type of glomerular lesions in mouse lupus nephritis.

Sasaki Y, Yamamoto Y, Miyazaki T, Ito MR, Nose M, Watanabe M.

Pathol Int. 2006 Mar;56(3):135-43.

PMID:
16497246
17.

Activation of the lectin pathway in murine lupus nephritis.

Trouw LA, Seelen MA, Duijs JM, Wagner S, Loos M, Bajema IM, van Kooten C, Roos A, Daha MR.

Mol Immunol. 2005 Apr;42(6):731-40.

PMID:
15781117
18.
19.

Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.

Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ.

J Immunol. 2000 Sep 15;165(6):3436-43.

20.

Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.

Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S.

Nephron. 1993;64(3):471-5.

PMID:
7688103
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk